AXSM250516P92500
- 1.11
- -0.71-39.01%
Axsome Therapeutics Newsroom
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $193
Earnings Preview: AXSM to Report Financial Results Pre-market on May 05
Axsome Therapeutics Price Target Raised to $193.00/Share From $190.00 by RBC Capital
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Axsome Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Alnylam Pharma (ALNY)
RBC Raises Price Target on Axsome Therapeutics to $193 From $190, Keeps Outperform Rating
Express News | Axsome Therapeutics Inc : UBS Cuts Target Price to $143 From $149
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Investors in Axsome Therapeutics (NASDAQ:AXSM) Have Seen Strong Returns of 235% Over the Past Three Years
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $190
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Axsome Therapeutics (AXSM) and Greenwich LifeSciences (GLSI)
Positive Outlook on Axsome Therapeutics' AXS-12 for Narcolepsy Treatment Amid Promising Phase III Results
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
New Analyst Forecast: $AXSM Given 'Buy' Rating
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Jefferies Initiates Coverage On Axsome Therapeutics With Buy Rating, Announces Price Target of $200
Jefferies Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $200
Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting